SLC5A2 and diabetic kidney disease: However, our data disprove this concept and suggest that the renoprotective effects of SGLT2 inhibition seen in diabetic kidney disease, does not occur in this non‐diabetic form of progressive CKD driven by primary tubulointerstitial injury.